Key Points

• CME Group Outage: CME Group halted trading across major futures and options markets after a data-center cooling failure, briefly freezing key benchmarks in oil, Treasurys and equity indices and highlighting operational risk in core market infrastructure.
• U.S. Drug Price Cuts: Newly negotiated Medicare prices under the Inflation Reduction Act will sharply cut U.S. list prices for blockbuster drugs such as Ozempic, increasing long-term U.S. margin pressure for Novo Nordisk, AstraZeneca, GSK and other global pharma names.
• Baidu’s AI Chip Push: Baidu’s Kunlunxin unit is emerging as a leading domestic AI chip supplier in China, positioned to capture strong, supply-constrained demand as U.S. curbs limit access to Nvidia GPUs.
• Trump’s Immigration Pledge: President Trump’s pledge to “permanently pause migration from all Third World Countries” and restrict benefits for noncitizens adds a new layer of U.S. policy uncertainty around immigration, labor supply and social stability.

CME Outage Halts Key Futures Markets, Tests Resilience of Global Price Discovery

The Chicago Mercantile Exchange temporarily halted trading across its Globex futures and options markets, FX platform EBS and BMD contracts after a cooling issue at a CyrusOne data center, freezing prices in benchmarks such as WTI crude, U.S. 10-year Treasurys and S&P 500 futures.

The disruption, hitting during a thin post-holiday session, is affecting Asian and European traders most and may delay visibility on moves in affected contracts until systems are fully restored.

While similar outages have occurred in the past, the episode highlights operational risk in increasingly concentrated market infrastructure and the potential for short-term distortions in liquidity and price discovery.

U.S. Drug Price Cuts Sharpen Focus on European Pharma’s U.S. Exposure

Medicare’s latest round of price negotiations under the Inflation Reduction Act is forcing European pharma majors to confront mounting U.S. pricing pressure just as the Trump administration pushes further with “Most Favored Nation” policies.

From 2027, Novo Nordisk’s Ozempic will see a 71% list-price cut for Medicare, while AstraZeneca’s Calquence and GSK’s Trelegy and Breo face 40%–83% discounts, trimming federal spending by an estimated 36%.

With 40%–55% of these firms’ sales tied to the U.S., investors must weigh margin compression against potential volume upside, particularly in fast-growing obesity drugs where lower prices could unlock broader access.

Baidu’s Kunlun Chips Move to the Center of China’s AI Push

Baidu is rapidly emerging as a key domestic AI chip player as Beijing looks to fill the gap left by U.S. curbs on Nvidia’s most advanced GPUs.

Through its Kunlunxin unit, Baidu is rolling out a five-year roadmap for Kunlun AI chips, already used alongside Nvidia hardware in its data centers to power ERNIE models and sold to third-party data center and telecom customers.

Analysts at Deutsche Bank and JPMorgan see Kunlun as one of China’s best-positioned AI chip platforms, with sales forecast to grow sixfold to around $1.1 billion by 2026 and potential valuation estimates near $28 billion, anchored by strong, supply-constrained domestic AI demand.

Trump Immigration Pledge Raises Policy Uncertainty After DC Shooting

President Trump signaled a sharper turn in U.S. immigration policy, vowing on social media to “permanently pause migration from all Third World Countries,” cancel federal benefits for noncitizens and broaden grounds for deportation, following a shooting near the White House involving an Afghan national.

The administration has already suspended immigration requests involving Afghan nationals and previously imposed a travel ban covering 19 countries.

While details and legal feasibility remain unclear, the escalation underscores rising policy risk around migration and labor flows, with potential implications for sectors reliant on immigrant workers and for broader perceptions of U.S. political and social stability.

Conclusion

Friday’s developments highlight how market plumbing, policy and technology are intersecting to reshape the investment landscape.

The CME outage is a reminder that operational risk in core trading infrastructure can briefly disrupt price discovery, even in otherwise calm conditions.

In healthcare, U.S. Medicare price cuts and “Most Favored Nation” ambitions sharpen the focus on U.S. earnings reliance for European pharma.

In China, Baidu’s Kunlun chips show how export controls are accelerating domestic AI ecosystems rather than stopping them.

Finally, sharp shifts in U.S. immigration rhetoric add another layer of uncertainty around future labor supply and political risk premia.

Investment Insights

• Pharma: Volume vs. Price in the U.S.: Medicare cuts and “Most Favored Nation” ideas confirm that high U.S. drug prices are under structural pressure.
• China AI: Hardware Shift, Not Demand Loss: Baidu’s rise in AI chips underlines that U.S. export controls are redirecting, rather than eliminating, Chinese AI investment. Exposure to AI should consider not just global leaders, but also regional ecosystems that are being forced to localize hardware and infrastructure.
• Immigration and Growth: Harsher U.S. immigration rhetoric raises questions for future labor supply, particularly in sectors reliant on foreign workers. Over time, tighter migration could support higher wage pressures and alter where global companies choose to base labor-intensive operations.

Economic Calendar